News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,314 Results
Type
Article (37574)
Company Profile (237)
Press Release (449503)
Multimedia
Podcasts (66)
Webinars (7)
Section
Business (136864)
Career Advice (1003)
Deals (24531)
Drug Delivery (85)
Drug Development (67948)
Employer Resources (95)
FDA (13119)
Job Trends (10420)
News (243001)
Policy (21869)
Tag
Academia (2039)
Academic (1)
Accelerated approval (6)
Adcomms (23)
Allergies (65)
Alliances (35652)
ALS (88)
Alzheimer's disease (1204)
Antibody-drug conjugate (ADC) (135)
Approvals (13095)
Artificial intelligence (235)
Autoimmune disease (26)
Automation (13)
Bankruptcy (186)
Best Places to Work (8854)
BIOSECURE Act (16)
Biosimilars (86)
Biotechnology (188)
Bladder cancer (80)
Brain cancer (28)
Breast cancer (278)
Cancer (2259)
Cardiovascular disease (177)
Career advice (841)
Career pathing (13)
CAR-T (176)
Cell therapy (492)
Cervical cancer (17)
Clinical research (55654)
Collaboration (807)
Company closure (1)
Compensation (377)
Complete response letters (25)
COVID-19 (1990)
CRISPR (49)
C-suite (220)
Cystic fibrosis (105)
Data (2166)
Denatured (11)
Depression (44)
Diabetes (229)
Diagnostics (4969)
Digital health (12)
Diversity (1)
Diversity, equity & inclusion (27)
Drug discovery (115)
Drug pricing (70)
Drug shortages (25)
Duchenne muscular dystrophy (101)
Earnings (57077)
Editorial (32)
Employer branding (15)
Employer resources (87)
Events (71726)
Executive appointments (609)
FDA (14318)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (677)
Gene editing (124)
Generative AI (22)
Gene therapy (362)
GLP-1 (615)
Government (2817)
Grass and pollen (3)
Guidances (138)
Healthcare (13914)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (118)
Indications (27)
Infectious disease (2106)
Inflammatory bowel disease (135)
Inflation Reduction Act (7)
Influenza (44)
Intellectual property (83)
Interviews (166)
IPO (12486)
IRA (22)
Job creations (2007)
Job search strategy (724)
Kidney cancer (10)
Labor market (17)
Layoffs (389)
Leadership (10)
Legal (4643)
Liver cancer (68)
Lung cancer (318)
Lymphoma (156)
Machine learning (7)
Management (28)
Manufacturing (266)
MASH (70)
Medical device (8525)
Medtech (8529)
Mergers & acquisitions (12591)
Metabolic disorders (628)
Multiple sclerosis (75)
NASH (17)
Neurodegenerative disease (94)
Neuropsychiatric disorders (30)
Neuroscience (1731)
NextGen: Class of 2025 (4217)
Non-profit (2931)
Now hiring (17)
Obesity (340)
Opinion (191)
Ovarian cancer (71)
Pain (81)
Pancreatic cancer (81)
Parkinson's disease (141)
Partnered (16)
Patents (206)
Patient recruitment (112)
Peanut (38)
People (38765)
Pharmaceutical (47)
Pharmacy benefit managers (14)
Phase I (17603)
Phase II (24571)
Phase III (18579)
Pipeline (1287)
Policy (100)
Postmarket research (1987)
Preclinical (7228)
Press Release (71)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (243)
Rare diseases (413)
Real estate (3247)
Recruiting (37)
Regulatory (16267)
Reports (25)
Research institute (2043)
Resumes & cover letters (167)
Rett syndrome (5)
RNA editing (5)
RSV (34)
Schizophrenia (70)
Series A (125)
Series B (81)
Service/supplier (6)
Sickle cell disease (58)
Special edition (11)
Spinal muscular atrophy (160)
Sponsored (28)
Startups (2647)
State (1)
Stomach cancer (15)
Supply chain (49)
Tariffs (26)
The Weekly (54)
Vaccines (546)
Venture capitalists (31)
Weight loss (219)
Women's health (21)
Worklife (5)
Date
Today (146)
Last 7 days (824)
Last 30 days (2645)
Last 365 days (28062)
2025 (10101)
2024 (30190)
2023 (33560)
2022 (42324)
2021 (45260)
2020 (41211)
2019 (32410)
2018 (24604)
2017 (24732)
2016 (22783)
2015 (26387)
2014 (18976)
2013 (22442)
2012 (15682)
2011 (16112)
2010 (14669)
Location
Africa (509)
Alabama (39)
Alaska (5)
Arizona (117)
Arkansas (7)
Asia (29749)
Australia (5260)
California (5460)
Canada (1664)
China (499)
Colorado (206)
Connecticut (251)
Delaware (126)
Europe (69496)
Florida (794)
Georgia (169)
Idaho (41)
Illinois (398)
India (25)
Indiana (246)
Iowa (6)
Japan (152)
Kansas (79)
Kentucky (24)
Louisiana (9)
Maine (43)
Maryland (740)
Massachusetts (4264)
Michigan (178)
Minnesota (304)
Mississippi (1)
Missouri (73)
Montana (17)
Nebraska (11)
Nevada (57)
New Hampshire (47)
New Jersey (1588)
New Mexico (23)
New York (1506)
North Carolina (869)
North Dakota (8)
Northern California (2444)
Ohio (165)
Oklahoma (7)
Oregon (23)
Pennsylvania (1158)
Puerto Rico (10)
Rhode Island (22)
South America (676)
South Carolina (14)
South Dakota (1)
Southern California (2022)
Tennessee (54)
Texas (765)
United States (20112)
Utah (161)
Virginia (118)
Washington D.C. (46)
Washington State (500)
West Virginia (3)
Wisconsin (46)
487,314 Results for "taysha gene therapies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
May 9, 2025
·
1 min read
Press Releases
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 2, 2025
May 5, 2025
·
2 min read
Press Releases
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
2 min read
Press Releases
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
February 26, 2025
·
11 min read
Press Releases
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 7, 2025
March 10, 2025
·
2 min read
Press Releases
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
February 19, 2025
·
1 min read
Gene therapy
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties
The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and discontinued partnerships.
May 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
2 min read
Business
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 14, 2024
·
13 min read
Lone Star Bio
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Taysha Gene Therapies, Inc. announced that, on June 3, 2024, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company’s common stock in connection with their employment.
June 7, 2024
·
2 min read
1 of 48,732
Next
